Trial · NCT01866930
Adverse events98
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 98
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Aspartate aminotransferase increased | Investigations | Cohort A: HCV GT-2 or GT-3 | 8 | 104 | 10 |
| other | Aspartate aminotransferase increased | Investigations | Cohort B: HCV GT-1 or GT-4 | 4 | 196 | 16 |
| other | Weight decreased | Investigations | Cohort A: HCV GT-2 or GT-3 | 4 | 104 | 5 |
| other | Weight decreased | Investigations | Cohort B: HCV GT-1 or GT-4 | 11 | 196 | 11 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Cohort A: HCV GT-2 or GT-3 | 4 | 104 | 4 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Cohort B: HCV GT-1 or GT-4 | 10 | 196 | 10 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort A: HCV GT-2 or GT-3 | 7 | 104 | 7 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort B: HCV GT-1 or GT-4 | 16 | 196 | 16 |
| other | Headache | Nervous system disorders | Cohort A: HCV GT-2 or GT-3 | 10 | 104 | 13 |
| other | Headache | Nervous system disorders | Cohort B: HCV GT-1 or GT-4 | 31 | 196 | 39 |
| other | Injection site erythema | General disorders | Cohort A: HCV GT-2 or GT-3 | 0 | 104 | 0 |
| other | Injection site erythema | General disorders | Cohort B: HCV GT-1 or GT-4 | 12 | 196 | 12 |
| other | Asthenia | General disorders | Cohort A: HCV GT-2 or GT-3 | 22 | 104 | 24 |
| other | Asthenia | General disorders | Cohort B: HCV GT-1 or GT-4 | 32 | 196 | 34 |
| other | Influenza like illness | General disorders | Cohort A: HCV GT-2 or GT-3 | 8 | 104 | 9 |
| other | Influenza like illness | General disorders | Cohort B: HCV GT-1 or GT-4 | 5 | 196 | 6 |
| other | Fatigue | General disorders | Cohort A: HCV GT-2 or GT-3 | 9 | 104 | 9 |
| other | Fatigue | General disorders | Cohort B: HCV GT-1 or GT-4 | 47 | 196 | 53 |
| other | Pyrexia | General disorders | Cohort A: HCV GT-2 or GT-3 | 3 | 104 | 4 |
| other | Pyrexia | General disorders | Cohort B: HCV GT-1 or GT-4 | 13 | 196 | 13 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01866930/events